WHY IS THIS STUDY IMPORTANT?

- Treatment for acromegaly aims to lower certain hormones – insulin-like growth factor 1 (IGF-1) and growth hormone (GH) – in the body and also reduce symptoms of acromegaly.
- When surgery, which is the usual first-line treatment, fails, medical treatment in the form of an injectable is often used.
- To our knowledge, paltusotine is the first nonpeptide once daily oral somatostatin agonist being evaluated for the treatment of acromegaly.
- For patients looking for an alternative to injections or twice-daily orals, paltusotine may reduce the burden of acromegaly treatment. Additionally, it may allow your doctor to determine an optimized dosing regimen more quickly compared with existing therapies.

Romina, diagnosed with acromegaly in 2016



Mike, diagnosed with acromegaly in 2016

HOW DO I GET MORE INFORMATION?

To find out more information about this study or paltusotine, contact the study team using the information provided below. Study participation is voluntary. By contacting us, you are not obligated to take part in the study nor complete the study if you would decide to participate.

VISIT OUR INTAKE PAGE:

at this QR code or go to bit.ly/3zzVOge

Study code: CRN00808-09
Study Sponsor: Crinetics Pharmaceuticals, Inc.

V4-29Apr2021

ACROMEGALY TREATMENT 24 HOURS 1 DOSE



Louis, diagnosed with acromegaly in 2020

A clinical study for an ORAL, ONCE-DAILY acromegaly treatment is looking for participants.

PATHFNDR 1

ABOUT THE STUDY

The purpose of this study is to see if the Sponsor's investigational medication, paltusotine, is safe and effective in controlling the IGF-1 levels in patients with acromegaly.

ABOUT ACROMEGALY

Acromegaly is a hormonal disorder that results from too much growth hormone (GH) in the body. GH is produced by a small gland in the brain called the pituitary gland. Usually, the GH excess comes from benign (noncancerous) tumors of the pituitary. The benign pituitary tumor that causes acromegaly makes too much GH and it affects your body by promoting abnormal growth of the bones of the hands, feet, face, jaw and soft tissues. These high GH levels can lead to a wide range of cardiovascular (heart and blood vessels issues, e.g. high blood pressure), respiratory (lungs), endocrine (hormone) and metabolic (e.g. diabetes – elevated blood sugar) illnesses, as well as joint pain, weakness, and sometimes visual disturbances.



VISIT THE TRIAL PAGE ON CLINICALTRIALS.GOV

Review the study summary, outcome measures, inclusion/exclusion criteria and more for the Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-1).

INTERESTED PARTICIPANTS MUST:

- Be 18 years of age or older
- Have medically stable, confirmed-active acromegaly
- Be on an approved, stable dose of long-acting octreotide or lanreotide, for at least 12 weeks prior to screening

INTERESTED PARTICIPANTS MAY RECEIVE:

- Study-related care and study medication at no cost
- Reimbursement for travel (patient +1)

WHAT ELSE DO I NEED TO CONSIDER?

- This is a Phase 3 clinical study testing an investigational medication.
- The study team can explain the possible benefits and risks of participating in this study.
- You do not have to take part in this study. If you decide to participate in this trial, you can choose to discontinue your involvement at any time.
- Participants are not paid to take part in the study, but the treatment, lab tests, and safety assessments are available at no cost.
- A team of medical professionals will monitor your acromegaly and your overall health throughout the study.

WHAT WILL THE STUDY INVOLVE?

This study includes a Screening Period and a Treatment Period. The Screening Period is up to 12 weeks and consists of 2 to 3 visits. After the Screening Period, subjects will be enrolled in a 36-week Treatment Period with approximately 11 planned visits.

Subjects will be divided by chance in a 1:1 ratio to receive either paltusotine or placebo (placebo tablets will look identical to the paltusotine tablets but not contain paltusotine or any other study medication).

At the end of the Treatment Period, subjects who in the opinion of the investigator may benefit from treatment with paltusotine, may be enrolled in a long-term, open label extension (OLE) for up to 96 weeks. During the OLE, all subjects will receive paltusotine.

Mike with his supportive wife Jackie